Searchable abstracts of presentations at key conferences in endocrinology

ea0021p172 | Diabetes and metabolism | SFEBES2009

Aldosterone production by the mouse adrenal gland is compromised by a high fat diet and 11β-hydroxysteroid dehydrogenase type 1 deficiency

Nilsson Frida , Morrison Hamish , Ramage Lynne , Morton Nicholas , Seckl Jonathan , Morley Steven , Kenyon Christopher

Deficiency of the intracellular glucocorticoid (GC) reactivating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) invokes compensatory activation of the HPA axis. Nevertheless, 11β-HSD1−/− mice resist dietary-induced obesity indicating that target tissues are protected from GC actions. Since endocrine adaptation to diet is mediated by altered HPA activity, we investigated whether the adrenal response to high fat (HF) diet is compr...

ea0015oc8 | Young Endocrinologist prize session | SFEBES2008

β-cell 11β-Hydroxysteroid dehydrogenase type 1 contributes to type 2 diabetes

Turban Sophie , Ramage Lynne , Paterson Janice , Mullins John , Seckl Jonathan , Morton Nik

High systemic cortisol levels contribute to insulin resistance and may exacerbate the development of diabetes by impairing the insulin secretory response of the pancreatic beta-cells (β-cells). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a key modulator of glucocorticoid effect within target tissues and high adipose or liver levels of this enzyme may contribute to obesity and/or metabolic disease. We investigated cellular localization of 11β-HSD1 ...

ea0011p385 | Diabetes, metabolism and cardiovascular | ECE2006

Dietary regulation of peripheral glucocorticoid action: comparison of saturated and unsaturated fats

Man TY , Ramage L , Gokcel A , Michailidou Z , Kenyon CJ , Chapman K , Seckl JR , Morton NM

Obesity/Metabolic syndrome (insulin resistance, hypertension, cardiovascular disease) has reached epidemic levels in western societies. Aberrantly elevated glucocorticoid amplification by intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) within adipose tissue might explain the striking similarities between idiopathic obesity/metabolic syndrome and Cushing’s syndrome, causes by plasma GC excess. A major contributor to obesity/metabol...

ea0010p42 | Endocrine tumours and neoplasia | SFE2005

Octreotide in the treatment of pthrp related hypercalcaemia in neuroendocrine tumours: a case report and literature review

Jones R , OaGrady J , Chambers S , Heaton N , Ramage J , Aylwin S

Intro: A subset of pancreatic and gastric neuroendocrine tumours (NET) are associated with hypercalcaemia attributed to tumour secretion of parathyroid hormone related peptide (PTHrP). Hypercalcaemia may be severe and refractory to conventional treatment....

ea0072p6 | (1) | UKINETS2020

Metachronous neuroendocrine neoplasms in England 2013–2015

White Benjamin E , Genus Tracey , Bouvier Catherine , Ramage John K , Srirajaskanthan Rajaventhan

Introduction: The aetiology of NENs vary; some are sporadic, others familial. An association between index NENs of the mid gut (ileum and colon) with subsequent colorectal primaries has been reported.Aim: We determined to evaluate the relationship between the diagnosis of an index primary malignancy and subsequent diagnosis of NEN.Methods: A population-based retrospective cohort study was under taken for persons with NEN diagnosis ...

ea0072p7 | (1) | UKINETS2020

Carcinoid heart surgery: Review of outcomes from a single large centre

Maclean Rory , Cope Jack , Hota Shweta , Mulholland Nicola , Ramage John , Wendler Olaf , Srirajaskanthan Raj

Introduction: Up to half of patients with carcinoid syndrome develop carcinoid heart disease; this is thought to be mediated by serotonin from disordered tryptophan metabolism. Valve degeneration can lead to right heart failure which drives morbidity and mortality in this patient population. Surgical replacement of affected valves is an effective therapy. Peptide receptor radiotargeted therapy (PRRT) has demonstrated better progression-free survival compared to high dose sando...

ea0096p25 | Section | UKINETS2023

Sequencing of treatment in G1-2 pancreatic neuroendocrine tumour - a case study

J Shi , D Sarker , J Mencel , R Srirajaskanathan , S Brown , D Clement , J Ramage , S Dolly

Herein, we present the case of a 48yo Caucasian male diagnosed with a well differentiated (WD) pancreatic NET. At primary resection in 2014 pathological staging was pT3N1M0 R0 with Ki67 4%. 5 years later he developed recurrence in local lymph nodes and started on lanreotide followed by IRE on subsequent progression. In 2020, there was strongly DPET-avid metastases in mesenteric nodes and liver, so he was enrolled onto the COMPETE trial1. There was sequential progressive diseas...

ea0096p26 | Section | UKINETS2023

Case report: a rectal neuroendocrine tumour with dynamic grade and clinical behaviour

Evan Theodore , Sarker Debashis , Mencel Justin , Srirajaskanthan Raj , Clement Dominique , Ramage John , Brown Sarah , Dolly Saoirse

Introduction: Neuroendocrine tumours (NETs) may change grade and clinical behaviour substantially over time, requiring shifts in management strategy.Case Presentation: A 53-year-old lady presented with abdominal bloating and diarrhoea. Diagnostic MRCP and CT-CAP confirmed metastatic cancer, with bilobar liver metastases and a sclerotic lesion in the right ilium. Her disease was 68Ga-DOTATATE-avid. Rectal biopsy confirmed...

ea0080OC1 | Oral Communications | UKINETS2021

Incidence, prevalence of survival of neuroendocrine neoplasia in England 1995–2018

White Benjamin E , Chandrakumaran Kandiah , Wong Kwok , Rous Brian , Bouvier Catherine , Van Hemelrijck Mieke , Srirajaskanthan Rajaventhan , Ramage John K

Introduction: Incidence of neuroendocrine neoplasia (NEN) is rising worldwide. The National Cancer Registry and Analysis Service allows accurate study of NEN in England. Aim: Calculate incidence and prevalence of NEN in England from 1995-2018. Calculate site-specific survival with multivariate analysis. Method: A population-based retrospective cohort study was performed. Data requested from NCRAS were reviewed by a steering group r...

ea0080p3 | Abstracts | UKINETS2021

Sex differences and survival of neuroendocrine neoplasia in England 2012–2018

White Benjamin E , Chandrakumaran Kandiah , Wong Kwok , Rous Brian , van Hemelrijck Mieke , Srirajaskanthan Rajaventhan , Ramage John K

Introduction: Sex differences have been noted at different sites of Neuroendocrine Neoplasia in previous registry studies across different countries. Analysis of National Cancer Registry and Analysis Service (NCRAS) data can help to clarify the significance and importance of this factor in England. Aim: To examine neuroendocrine neoplasia incidence and survival by sex, site and stage. Method: A population-based, cohort study was pe...